We provide you with 20 years of free, institutional-grade data for ONCT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ONCT. Explore the full financial landscape of ONCT stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about ONCT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Oncternal Therapeutics, Inc(NASDAQ:ONCT) 
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in ...
Website: http://www.oncternal.com
Founded: 1997
Full Time Employees: 11
CEO: James B. Breitmeyer
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends